A novel nuclear receptor ligand, digoxigenin, is a selective antagonist of liver-X-receptors

Haruka Oishi, Yousuke Takaoka, Tomoko Nishimaki-Mogami, Hiroaki Saito, Minoru Ueda

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Recent progress in chemical biology of natural products has revealed the multiligandable nature, and exploration of new natural product targets often leads to the discovery of novel drug leads. We focused on digoxigenin (1), which is an aglycone of the steroid glycoside digoxin. The in vitro binding assay using the ligand binding domain of nuclear receptors indicated that 1 is a potential antagonist of liver-X-receptors, a result that was supported by an in silico docking study.

Original languageEnglish
Pages (from-to)313-314
Number of pages2
JournalChemistry Letters
Volume46
Issue number3
DOIs
Publication statusPublished - 2017 Jan 1

Keywords

  • Drug discovery
  • Natural products
  • Nuclear receptor

ASJC Scopus subject areas

  • Chemistry(all)

Fingerprint Dive into the research topics of 'A novel nuclear receptor ligand, digoxigenin, is a selective antagonist of liver-X-receptors'. Together they form a unique fingerprint.

Cite this